News - Longevity.Technology

Genentech, Alector partner ...

Coya Therapeutics completes...

Alterity’s Parkinson’s drug...

Genflow presents interim re...

BodySpec opens body composi...

Genentech, Alector partner ...

Coya Therapeutics completes...

Alterity’s Parkinson’s drug...

Genflow presents interim re...

BodySpec opens body composi...

Ecosystem

‘Show me the error bars before you sell me longevity’

Diagnostics

Mito adds a $249 heart scan. Who needs one?

Ecosystem

Reflections from ARDD 2026

Biotech

Immorta Bio picked for NYU Stern startup program

Biotech

FDA approves new kind of Parkinson’s pill from AbbVie

Diagnostics

Two very different Alzheimer’s tests just teamed up

Biotech

REGENXBIO’s diabetic eye gene therapy reaches three-year mark

Biotech

Lilly and Novo share GLP-1 longevity data

Biotech

The future of peptide medicine is about closing the gray market

Genentech, Alector partner on $1.2b Parkinson’s drug deal

Coya Therapeutics completes enrollment in ALSTARS ALS trial

Alterity’s Parkinson’s drug trial shows slowed clinical decline, advances to Phase 3

Genflow presents interim results from aging-dog SIRT6c study

BodySpec opens body composition scanning storefront in downtown Oakland

Atrogi reports early trial success for drug that cuts fat while building muscle

Digbi Health combines hormone therapy, GLP-1 care in single app

Your daily longevity briefing

The latest longevity science, investment, innovation and insights-delivered every morning.

‘Show me the error bars before you sell me longevity’

Immorta Bio picked for NYU Stern startup program

The exit math forcing an M&A decade

Junevity takes gene-network reset into skincare

Longevity biotech’s $173 billion in waiting

The $230 billion nobody needs to approve

BioViva patents dual-gene approach to aging

CND Life Sciences opens new neurodiagnostics lab

Immorta Bio picked for NYU Stern startup program

FDA approves new kind of Parkinson’s pill from AbbVie

REGENXBIO’s diabetic eye gene therapy reaches three-year mark

Lilly and Novo share GLP-1 longevity data

The future of peptide medicine is about closing the gray market

Annovis turns to AI to fast-track its Alzheimer’s filing

Japan’s parsley-powered bet on aging among XPRIZE finalists

Insilico picks AI-designed GIPR blocker for next obesity drug

Genflow gene therapy nudges aging clock in dogs

Basecamp raises $140m to teach AI all of biology

Johns Hopkins team wins $1m XPRIZE for immune aging research

Serina’s new Parkinson’s therapy clears first safety hurdle

Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

When supplements don’t make it past the gut

Elivity brings spray-based supplements to Asia

PhytoGaia puts palm fruit at the heart of healthy aging

Can we prime skin to regenerate better?

‘Show me the error bars before you sell me longevity’

The future of peptide medicine is about closing the gray market

Reflections from ARDD 2026

Longevity awards reflect a widening field